Key Details
Price
$30.48Annual Revenue
$509.34 MAnnual EPS
-$1.95Annual ROE
-51.52%Beta
1.76Events Calendar
Next earnings date:
Feb 21, 2025Recent quarterly earnings:
Oct 30, 2024Recent annual earnings:
Feb 22, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Cancer-targeting biotech NovoCure (NVCR -9.00%) had some highly positive news from the laboratory to deliver earlier this week, and investors couldn't grab hold of the stock fast enough. This momentum was helped by price target increases from analysts.
The life science industry recently gave folks diagnosed with pancreatic cancer the best news this group has received in a very long time. A new treatment option that significantly raises their chances for long-term survival could become widely available next year.
Novocure stock soars 49% as the late-stage study of TTFields therapy for treating pancreatic adenocarcinoma meets the primary endpoint of overall survival.
On Monday, NovoCure Ltd NVCR and Zai Lab Limited ZLAB revealed topline data from the Phase 3 PANOVA-3 trial of Tumor-Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.
Novocure said on Monday its experimental therapy extended the lives of patients with a form of advanced pancreatic cancer when combined with chemotherapy, achieving the primary goal in a late-stage trial.
SHANGHAI & CAMBRIDGE, Mass. & ROOT, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control. PANOVA-3 evaluated the use of Tumor Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally adv.
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to participate in upcoming investor conferences.
NovoCure Limited (NASDAQ:NVCR ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Ingrid Goldberg - IR Bill Doyle - Chairman Ashley Cordova - CFO Asaf Danziger - CEO Frank Leonard - EVP and President of NovoCure Oncology Nicolas Leupin - Chief Medical Officer Conference Call Participants Jason Bednar - Piper Sandler Jonathan Chang - Leerink Partners Emily Bodnar - H.C. Wainwright Jessica Fye - JPMorgan Operator Good day, and thank you for standing by.
NovoCure (NVCR) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.46 per share a year ago.
NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
FAQ
- What is the primary business of NovoCure Limited?
- What is the ticker symbol for NovoCure Limited?
- Does NovoCure Limited pay dividends?
- What sector is NovoCure Limited in?
- What industry is NovoCure Limited in?
- What country is NovoCure Limited based in?
- When did NovoCure Limited go public?
- Is NovoCure Limited in the S&P 500?
- Is NovoCure Limited in the NASDAQ 100?
- Is NovoCure Limited in the Dow Jones?
- When was NovoCure Limited's last earnings report?
- When does NovoCure Limited report earnings?
- Should I buy NovoCure Limited stock now?